via lanecc.edu
Researchers from the University of Copenhagen and biotech firm Gubra have developed a new insulin molecule that will make blood sugar regulation both easier and safer for those with type 1 diabetes.
Everyday life for the more than 46 million people around the world who suffer from type 1 diabetes could become much easier and safer.
Researchers from the University of Copenhagen and biotech firm Gubra have developed a new insulin molecule that, in the future, will ensure that diabetics receive just the right amount of insulin.
The insulin on the market today is unable to identify whether a patient with type 1 diabetes needs a small or large effect from the insulin, which lowers blood sugar.
“That is why we have developed the first step towards a kind of insulin that can self-adjust according to a patient’s blood sugar level. This has tremendous potential to vastly improve the lives of people with type 1 diabetes,” explains Professor Knud J. Jensen, of the University of Copenhagen’s Department of Chemistry, one of the researchers behind a new study on this new insulin.
Effective in rats
The researchers behind the study developed a type of insulin with a built-in molecular-binding that can sense how much blood sugar is in the body. As blood sugar rises, the molecule becomes more active and releases more insulin. As blood sugar drops, less is released.
“The molecule constantly releases a small amount of insulin, but varies according to need,” says Knud J. Jensen, who continues:
“It will give type 1 diabetes patients a safer and easier treatment. Today, a person with type 1 diabetes must inject themselves with insulin many times throughout the day and frequently monitor their blood sugar level by pricking their finger with a blood glucose meter. This here, allows a person to inject the new insulin molecule less often over the course of a day and thereby think about it less,” says Knud J. Jensen.
Although the new ‘automated’ insulin is a major advance towards better diabetes treatment, it will be a while before the revolutionary insulin becomes a part of diabetics’ everyday lives.
“We’ve tested the insulin molecule on rats and it has proven itself effective. The next step is to develop the molecule so that it works more rapidly and accurately. And finally, to test it in humans — a process that can take many years. But it is certainly worth pinning one’s hopes on,” explains Professor Jensen.
An idea that sprouted in the United States
The idea to create a kind of insulin that self-adjusts to a patient’s needs occurred many years ago, while Professor Jensen was living in the United States. This is where a friend of his with type 1 diabetes recounted to him a story:
“My author friend Jan Sonnergaard told me about a married couple who had been dancing one night. The man had type 1 diabetes and was feeling unwell. The wife thought to stabilise his blood sugar by giving him insulin. Unfortunately, the insulin eventuated in her husband’s death. I wanted to make certain that this kind of tragedy would never be repeated,” says Knud J. Jensen, concluding:
“The difficult thing with diabetes is that insulin always works the same way. It lowers blood sugar, even though that might not be what a patient requires. This is what we seek to address with our new molecule.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Insulin molecule
- Two views of elusive diabetes drug target
Binding of the peptide hormone GLP-1 activates the receptor, causing cell signaling that helps regulate glucose metabolism and insulin release from the pancreas ... now help drug designers develop ...
- Team develops automated platform for plasmid production
Plasmids have extensive use in basic and applied biology. These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Well known for their applications in ...
- Diabetes Care Devices Market Size In 2022 : Top Countries Data, SWOT Analysis, Share, Top Manufactures, Growth Insights and Forecasts to 2026
Insulin is a hormone secret by the beta cell of the islet of Langerhans of the pancreas. When your body turns the food which u eat into energy molecule glucose. In response to glucose, body secretes ...
- Biomaterial Prevents Rejection of Islet Grafts for Diabetes Therapy
Pancreatic islets transplanted in a biomaterial that contains an immune tolerance-promoting protein tethered to the surface of microgel beads.
- Novel Type 1 diabetes treatment involves transplantation of insulin-producing pancreas cells
In a new study, a team of researchers from the University of Missouri, Georgia Tech and Harvard University has demonstrated the successful use of a novel Type 1 diabetes treatment in a large animal ...
Go deeper with Google Headlines on:
Insulin molecule
Go deeper with Bing News on:
Blood sugar regulation
- Diabetes type 2: Sensations warning of worsening blood sugar levels – 'see your doctor'
DIABETICS are responsible for managing blood sugar levels with diet and exercise. Falling out of kilter can be extremely damaging, but would you recognise the warning signs?
- FDA approves diabetes drug with evidence of superior blood sugar control
Tirzepatide (Mounjaro), made by Eli Lilly, is indicated along with diet and exercise for use in improving blood sugar control in adults, the agency announced Friday. It is administered under the skin ...
- 5 Best Recipes to Help Lower Blood Sugar, Says Dietitian
If you're looking for some blood sugar-friendly recipe inspiration, we rounded up five recipes that can help lower blood sugar.
- Diabetes: Controlling blood sugar levels quickly ‘significantly’ prevents heart attacks
DIABETES is an increasingly common condition in the UK, one that requires careful management. As with other conditions, diabetes can affect a person's likelihood of experiencing cardiovascular events ...
- FDA approves Tirzepatide for controlling blood sugar in type 2 diabetes patients
The US Food and Drug Administratio has granted approval to tirzepatide (Mounjaro) injection for treatment of patients with type 2 diabetes. Tirzepatide is a novel, dual-targeted treatment ...